PharmaEssentia to Present New Clinical Data Supporting Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Key claim: New two-year data from the Phase 3 SURPASS-ET trial compare early versus delayed ropeginterferon alfa-2b initiation in ET and analyze outcomes in patients transitioning from anagrelide.
Abstract
PharmaEssentia will present new analyses from the Phase 3 SURPASS-ET study of ropeginterferon alfa-2b in patients with ET, including two-year outcomes comparing early versus delayed initiation and post-hoc analyses of patients who transitioned from anagrelide. The ASCO annual meeting will be held May 29-June 2 in Chicago, and the EHA2026 Congress will be held June 11-14 in Stockholm, Sweden.
Why this matters
Two-year SURPASS-ET data extend the durability evidence for ropeginterferon alfa-2b in ET beyond the initial 9–12 month response window, directly informing the natural history of treated HU-intolerant/refractory ET. The early-vs-delayed initiation analysis is particularly relevant to whether interferon-based disease modification alters long-term ET trajectory, while the anagrelide-transition subset clarifies sequencing in a subtype where second-line options (ropeginterferon, bomedemstat, STP938, CALR-directed agents) are rapidly expanding.